Journal: Postępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
Article Title: The influence of acute coronary syndrome on levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19*2(681 G>A), *3(636 G>A) and ABCB1(C3435C> T) gene polymorphisms
doi: 10.5114/aic.2021.106894
Figure Lengend Snippet: Levels of clopidogrel active metabolite in: A – the whole study group and subgroups; B – patients with ST-segment elevation myocardial infarction (STEMI) and STEMI subgroups; C – patients with non-ST-segment elevation myocardial infarction (NSTEMI) and NSTEMI subgroups Control – control group, GA – good absorbers, PA – poor absorbers, LoF – loss of function alleles, NoF – normal function alleles, NSTEMI – non-ST-segment elevation myocardial infarction, STEMI – ST-segment elevation myocardial infarction, Total – whole population.
Article Snippet: The MPB-derivatized clopidogrel active metabolite hydrochloride and [13C6]-(±)-clopidogrel carboxylic acid (internal standard) were purchased from Alsachim (Illkirch-Graffenstaden, France).
Techniques: